Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

Overview of attention for article published in Diabetes Therapy, March 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 93 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Article in Kidney International (November 2022)

Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol

Article in JBI Evidence Synthesis (July 2022)

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Article in Applied Health Economics and Health Policy (March 2022)